Table 1 Patient demographic and clinical characteristics.

From: The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O172)

Variable

Whole cohort (n = 117)

Blinatumomab (n = 31)

No Blinatumomab (n = 86)

P-value

Age (median, range)

40 (18–70)

35 (18–65)

40 (19–70)

0.9

Gender (n, %)

   

1.0

 Female

60 (51.3%)

16 (51.6%)

44 (51.2%)

 

 Male

57 (48.7%)

15 (48.4%)

42 (48.8%)

 

Diagnosis (n, %)

   

0.01

 Ph+ve

50 (42.7%)

7 (22.6%)

43 (50.0%)

 

 Ph-ve

67 (57.3%)

24 (77.4%)

43 (50.0%)

 

Pediatric inspired protocol (n, %)

   

0.61

 Yes

112 (95.7%)

29 (93.5%)

83 (96.5%)

 

 No

5 (4.3%)

2 (6.5%)

3 (3.5%)

 

Indication of transplant (n, %)

   

<0.001

 Relapse

33 (28.9%)

16 (51.6%)

17 (20.5%)

 

 Primary induction failure

20 (17.5%)

14 (45.2%)

6 (7.2%)

 

 Chemotherapy intolerance

2 (1.8 %)

0 (0.0%)

2 (2.4%)

 

 High-risk features

45 (39.5%)

0 (0.0%)

45 (54.2%)

 

 Therapy-related

10 (8.8%)

1 (3.2%)

9 (10.8%)

 

 MRD positivity after chemotherapy

4 (3.5%)

0 (0.0%)

4 (4.8%)

 

Donor (n, %)

   

0.13

 MRD

36 (30.8%)

10 (32.3%)

26 (30.2%)

 

 MUD

47 (40.2%)

11 (35.5%)

36 (41.9%)

 

 MMUD

17 (14.5%)

2 (6.5%)

15 (17.4%)

 

 HID

17 (14.5%)

8 (25.8%)

9 (10.5%)

 

Graft (n, %)

   

1.0

 PBSC

112 (95.7%)

30 (96.8%)

82 (95.3%)

 

 BMSC

5 (4.3%)

1 (3.2%)

4 (4.7%)

 

CMV discordance

   

0.5

 No

74 (63.2%)

18 (58.1%)

56 (65.1%)

 

 Yes

43 (36.8%)

13 (41.9%)

30 (34.9%)

 

 HCT-CI (median, range)

1 (0–8)

1 (0-8)

1 (0-7)

1.0

 KPS (median, range)

90 (60-100)

90 (60-100)

90 (70-100)

0.3

DRI (n, %)

   

<0.001

 Intermediate

80 (68.4%)

11 (35.5%)

69 (80.2%)

 

 High

36 (30.8%)

19 (61.3%)

17 (19.8%)

 

 Very high

1 (0.8%)

1 (3.2%)

0 (0.0%)

 

Conditioning (n, %)

   

0.08

 MAC

77 (65.8%)

16 (51.6%)

61 (70.9%)

 

 RIC

40 (34.2%)

15 (48.4%)

25 (29.1%)

 

GVHD prophylaxis (n, %)

   

<0.001

 T-Cell depletion

84 (71.8%)

30 (96.8%)

54 (62.8%)

 

 Other

33 (28.2%)

1 (3.2%)

32 (37.2%)

 

TBI 1200 (n, %)

   

0.2

 Yes

49 (41.9%)

16 (51.6%)

33 (38.4%)

 

 No

68 (58.1%)

15 (48.4%)

53 (61.6%)

 

Inotuzumab (n, %)

   

0.01

 Yes

7 (6.0%)

5 (16.1%)

2 (2.3)

 

 No

110 (94.0%)

26 (83.9%)

84 (97.7%)

 
  1. BMSC bone marrow stem cells, CMV cytomegalovirus, DRI disease risk index, HCT-CI hematopoietic cell transplant comorbidity index, HID haploidentical donor, KPS Karnofsky performance status, MAC myeloablative conditioning, MMUD mismatched unrelated donor, MRD matched related donor, MUD matched unrelated donor, PBSC peripheral blood stem cells, RIC reduced intensity conditioning, TBI total body irradiation.
Back to article page